Quest Diagnostics
DGX
A$257.71
Share price
0.05%
Change (1 day)
18.60%
Change (1 year)
Categories
Quest Diagnostics is an American clinical laboratory company offering access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders and employment and court ordered drug testing.
Quest Diagnostics (DGX) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : A$13.43 Billion
According to Quest Diagnostics 's latest financial reports the company's total liabilities are A$13.43 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Quest Diagnostics - Total liabilities on balance sheet (from 2001 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | A$14.88 B | 33.34% |
| 2023-12-31 | A$11.16 B | 11.2% |
| 2022-12-31 | A$10.03 B | 3.23% |
| 2021-12-31 | A$9.72 B | 4.78% |
| 2020-12-31 | A$9.27 B | -8.24% |
| 2019-12-31 | A$10.11 B | 25.88% |
| 2018-12-31 | A$8.03 B | 14.69% |
| 2017-12-31 | A$7.00 B | -5.86% |
| 2016-12-31 | A$7.44 B | 4.65% |
| 2015-12-31 | A$7.10 B | 5.27% |
| 2014-12-31 | A$6.75 B | 21.08% |
| 2013-12-31 | A$5.57 B | 13.69% |
| 2012-12-31 | A$4.90 B | -10.15% |
| 2011-12-31 | A$5.45 B | 23.98% |
| 2010-12-31 | A$4.40 B | -13.09% |
| 2009-12-31 | A$5.06 B | -25.5% |
| 2008-12-31 | A$6.80 B | 13.46% |
| 2007-12-31 | A$5.99 B | 78.86% |
| 2006-12-31 | A$3.35 B | -3.56% |
| 2005-12-31 | A$3.47 B | 40.44% |
| 2004-12-31 | A$2.47 B | -3.52% |
| 2003-12-31 | A$2.56 B | -7.08% |
| 2002-12-31 | A$2.76 B | -11.64% |
| 2001-12-31 | A$3.12 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 LabCorp LH | A$14.24 B | 6.03% | 🇺🇸 USA |
 Psychemedics PMD | A$4.89 M | -99.96% | 🇺🇸 USA |
 NeoGenomics
NEO | A$1.09 B | -91.85% | 🇺🇸 USA |
 Enzo Biochem ENZB | A$30.87 M | -99.77% | 🇺🇸 USA |
 Qiagen QGEN | A$3.28 B | -75.58% | 🇳🇱 Netherlands |